Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIMOSA trial of monalizumab plus trastuzumab in metastatic HER2-positive breast cancer
NL-OMON52889Phase 2Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of monalizumab, trastuzumab in breast cancer, sponsored by Netherlands Cancer Institute. Started Mar 2021; status: active, not recruiting.
02
Drugs
monalizumabtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON52889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52889.